



18 December 2014
EMA/790636/2014
Human Medicines Evaluation

Overview of (invented) names reviewed in November 2014 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 15 - 18 December 2014

	NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		2014	
	29 Jan 2014		26 Mar 2014		15 May 2014		02 July 2014		01 Oct 2014		26 Nov 2014		Accepted	Rejected
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed invented names	35	37	47	41	54	32	61	54	48	37	77	52	322	253
Justification for retention of invented name *	1	6	0	5	1	9	2	4	3	0	3	4	10	28

*In case of objections to the proposed invented name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.



	NRG meeting 29 Jan 2014		NRG meeting 26 Mar 2014		NRG meeting 15 May 2014		NRG meeting 02 July 2014		NRG meeting 01 Oct 2013		NRG meeting 26 Nov 2014		2014	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Objections														
Total number of objections raised	76	45	82	53	47	38	114	65	65	28	101	39	485	268
Criterion - Safety concerns														
Similarity with other Invented name	62	36	72	46	42	28	96	53	52	22	90	38	414	223
Conveys misleading therapeutic/pharmaceutical connotations		1		1		1	1					1	1	4
Misleading with respect to composition						2			1		1		2	2
Criterion - INN concerns														
Similarity with INN	4	1	4	2	2	1	9	3	7	4	2		28	11
Inclusion of INN stem	3		4	3		1	3				3		13	4
Criterion - Other public health concerns														
Unacceptable qualifiers	2					1					1		3	1
Conveys a promotional message	2	4				1	5	4	1				8	9
Appears offensive or has a bad connotation	1	1			1				1				3	1
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations														
Similarity between name of prodrug and related active substance														
Others	2	2	2	1	2	3		5	3	2	4		13	13

See *Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (CPMP/328/98 Rev. 5)* for detailed explanations of criteria used.